Editorial

Novel Drugs Breaks Down Barriers – Attacks Breast Cancer Cells from Inside Out

Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From Oxford BioTherapeutics’ –...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical...

Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration

Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for...

Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or Refractory HL and...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy...

Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects and Hints at...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or...

Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma Shows Positive Results With Brentuximab Vedotin...

Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30...

FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In Mid 2012

Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for...

Investigational Antibody-Drug Conjugate, Shows Encouraging Results in Women With Highly Advanced HER2-positive Breast Cancer

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug...